Feature | November 06, 2013

MedStar Heart Institute, Infraredx Initiate Lipid Rich Plaque Study to Evaluate Prediction of Heart Attacks

Positive results with the Infraredx Near-Infrared Spectroscopy (NIRS) TVC coronary imaging system led to the decision to launch 9,000-patient trial

Infraredx TVC Imaging System, Infraredx, TVC Imaging System

Infraredx TVC Imaging System

November 6, 2013MedStar Heart Institute of Washington, D.C. and Infraredx, Inc. announced the initiation of the Lipid-Rich Plaque (LRP) Study, a prospective, multi-center study designed to evaluate the ability of intravascular imaging to identify patients with LRPs who are at a higher risk for heart attacks and other serious coronary events. LRPs are a type of fatty coronary artery plaque implicated in most heart attacks, and will be identified using the Infraredx TVC Imaging System, a first-in-class catheter-based intravascular imaging technology. The study, which will be sponsored by Infraredx, seeks to enroll 9,000 patients, and will examine the correlation between the presence of LRPs and the occurrence of a cardiac event during the 24 months after imaging. MedStar Heart Institute is one of 100 clinical sites across the country to participate in the trial.

The TVC system integrates near-infrared spectroscopy (NIRS) lipid core plaque detection technology, and enhanced intravascular ultrasound (IVUS) imaging to visualize the presence of plaques, quantify the degree of vessel stenosis (narrowing) and identify plaques suspected to be prone to rupturing and causing dangerous blockages. Current methods of diagnosing coronary artery disease are limited in their ability to detect such plaques.

A recent study [1] published in the Journal of the American College of Cardiology Cardiovascular Interventions, demonstrated that NIRS imaging detected a distinct signature of a cholesterol plaque at the sites causing major heart attacks. A second study [2] found that increased cholesterol (detected by NIRS imaging) in a non-culprit artery indicated the patient had a four-fold multivariate increase in risk of a coronary event over the subsequent year.

“This innovative and uniquely designed study will finally answer the decades-old question of whether or not we can accurately identify a vulnerable plaque” said Ron Waksman, M.D., director, cardiovascular research and advanced education with MedStar Heart Institute, and the international principal investigator of the LRP study. “The LRP study will utilize the TVC system to identify lipid rich plaques in patients undergoing stenting. We will then follow the patients for two years to determine if these suspected vulnerable plaques cause coronary events.”

“Successful prediction in the study will permit us to identify patients and lesions at increased risk,” said Waksman. “We can then utilize treatment modalities, drug or device, or a combination, to help mitigate this risk.”

The study will be conducted in approximately 100 hospitals located throughout the world. Dr. Carlo Di Mario of London, England will serve as Principal investigator for Europe. Dr. Takeshi Akasaka of Wakayama, Japan will serve as Principal Investigator for Japan, a country with advanced coronary imaging experience. Dr. Yasunori Ueda of Osaka, Japan will serve as co-principal investigator for Japan.

The LRP study will start enrollment in December 2013 and conclude follow-up for the last patient in December 2017. The study will initially focus on validating the ability of NIRS-IVUS imaging to predict coronary events. If and when that goal is achieved, the study will transition to a blinded, randomized study of TVC-guided preventive treatment.

For more information: www.infraredx.com


1. Madder et al, JACC Interventions 2013

2. Oemrawsingh et al, European Heart Journal, in press 2013

Related Content

coherex Wave Crest LAA Occluder

Coherex WaveCrest Left Atrial Appendage (LAA) Occlusion System.

News | November 24, 2015
November 24, 2015 — Biosense Webster announced it has acquired Coherex Medical Inc., a privately held medical device
Feature | Cath Lab| November 24, 2015
November 24, 2015 — The U.S.
News | Heart Valve Repair| November 23, 2015
NaviGate Cardiac Structures Inc. (NCSI) announced that a first-in-human implant of its catheter-guided, mitral-valved...
Boston Scientific, Watchman FLX, LAA closure device, CE mark, first European implants

Image courtesy of Boston Scientific

News | Left Atrial Appendage (LAA) Occluders| November 20, 2015
Boston Scientific announced the first implants of the Watchman FLX left atrial appendage closure (LAAC) device
protein reprogramming, Stem Cells Translational Medicine, cardiac progenitor cells, CPCs, regenerative therapies
News | Stem Cell Therapies| November 13, 2015
A new study appearing in STEM CELLS Translational Medicine (SCTM) describes a highly efficient, protein-based method...
angina, abnormal heart blood flow, female-pattern heart disease, Cedars-Sinai Heart Institute study, AHA Scientific Sessions
News | Cardiac Diagnostics| November 13, 2015
Chest pain in female-pattern heart disease is linked with abnormal heart blood flow, a new Cedars-Sinai Heart Institute...
News | Antiplatelet and Anticoagulation Therapies| November 12, 2015
Preventing blood clots with drugs such as heparin has become a common practice for fighting some heart and lung...
pharmacist-physician collaboration, high blood pressure control, minority and low-income populations
News | Hypertension| November 12, 2015
November 12, 2015 — A pharmacist-physician collaborative effort to control blood pressure among a diverse group of pa
obese kids, eight years old, heart disease, MRI, Linyuan Jing
News | Cardiac Diagnostics| November 11, 2015
Imaging tests of obese children — some as young as 8 years old — showed signs of significant heart disease and heart...
Overlay Init